Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has provided an announcement.
Sihuan Pharmaceutical Holdings Group announced a share repurchase plan of up to HK$500 million, with the recent repurchase of 10 million shares at an average price of HK$0.6888 per share. This move is part of the company’s strategy to enhance shareholder value and reflects its confidence in future growth. Sihuan has made significant progress in its medical aesthetics and pharmaceuticals segments, with substantial revenue growth and new product approvals. The company anticipates these developments will positively impact its revenue and profit, reinforcing its position in the industry.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group, founded in 2001 and listed on the Main Board of the Stock Exchange in 2010, is an international company focused on medical aesthetics and biopharmaceuticals. It is driven by innovation with a strong research and development platform, a comprehensive product pipeline, and an efficient sales system. The company aims to be a leader in China’s medical aesthetics and biopharmaceutical sectors.
YTD Price Performance: 6.06%
Average Trading Volume: 30,528,440
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.53B
See more data about 0460 stock on TipRanks’ Stock Analysis page.